DoubleLine ETF Adviser’s Biogen BIIB Stock Holding History

DoubleLine ETF Adviser’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$390K	Buy	+2,125	New	+$392K	0.15%	135

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DoubleLine ETF Adviser's BIIB Position: Q1 2026 in Review

DoubleLine ETF Adviser opened a new position in Biogen (BIIB) in Q1 2026: 2,125 shares worth $390K. The stake represents 0.15% of the portfolio and ranks #135 among its holdings.

1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

DoubleLine ETF Adviser held 2,125 shares of Biogen worth $390K as of Q1 2026.
Biogen was a new DoubleLine ETF Adviser position in Q1 2026.
Biogen made up 0.15% of DoubleLine ETF Adviser's portfolio in Q1 2026, its #135 holding.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q1 2026, filed 15 May 2026.